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Abstract
Background: The use of early morning sputum samples (EMS) to diagnose tuberculosis (TB) can result in treatment
delay given the need for the patient to return to the clinic with the EMS, increasing the chance of patients being
lost during their diagnostic workup. However, there is little evidence to support the superiority of EMS over spot
sputum samples. In this new analysis of the REMoxTB study, we compare the diagnostic accuracy of EMS with spot
samples for identifying Mycobacterium tuberculosis pre- and post-treatment.
Methods: Patients who were smear positive at screening were enrolled into the study. Paired sputum samples
(one EMS and one spot) were collected at each trial visit pre- and post-treatment. Microscopy and culture on
solid LJ and liquid MGIT media were performed on all samples; those missing corresponding paired results were
excluded from the analyses.
Results: Data from 1115 pre- and 2995 post-treatment paired samples from 1931 patients enrolled in the REMoxTB
study were analysed. Patients were recruited from South Africa (47%), East Africa (21%), India (20%), Asia (11%), and
North America (1%); 70% were male, median age 31 years (IQR 24–41), 139 (7%) co-infected with HIV with a median CD4
cell count of 399 cells/μL (IQR 318–535). Pre-treatment spot samples had a higher yield of positive Ziehl–Neelsen smears
(98% vs. 97%, P = 0.02) and LJ cultures (87% vs. 82%, P = 0.006) than EMS, but there was no difference for positivity
by MGIT (93% vs. 95%, P = 0.18). Contaminated and false-positive MGIT were found more often with EMS rather
than spot samples. Surprisingly, pre-treatment EMS had a higher smear grading and shorter time-to-positivity, by
1 day, than spot samples in MGIT culture (4.5 vs. 5.5 days, P < 0.001). There were no differences in time to positivity in pre-
treatment LJ culture, or in post-treatment MGIT or LJ cultures. Comparing EMS and spot samples in those
with unfavourable outcomes, there were no differences in smear or culture results, and positive results were not
detected earlier in Kaplan–Meier analyses in either EMS or spot samples.
Conclusions: Our data do not support the hypothesis that EMS samples are superior to spot sputum samples in a
clinical trial of patients with smear positive pulmonary TB. Observed small differences in mycobacterial burden are of
uncertain significance and EMS samples do not detect post-treatment positives any sooner than spot samples.
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Background
In resource-limited areas, travel time and costs associ-
ated with accessing healthcare facilities can be a consid-
erable burden to patients being investigated for
tuberculosis (TB) and their families [1–3]. The financial
burden can equal several months’ salary and may there-
fore exacerbate or push people into poverty [4, 5].
These costs apply equally to patients found to have TB,
and to the vast majority who have an alternative cause
for their symptoms. Given 50 million smear investiga-
tions for TB are undertaken every year [6], this may
have powerful consequences for global health. Further-
more, a substantial proportion of patients are ‘lost’ dur-
ing the diagnostic pathway and fail to commence TB
treatment [7–10], risking poorer treatment outcomes
and presenting a continuing reservoir for transmission
of TB in the community.
The diagnosis of TB is largely based on smear micros-
copy of expectorated sputum samples, and will likely
continue to be so in those resource-limited settings un-
able to afford the roll-out of Xpert MTB/RIF (Cepheid,
Sunnyvale, CA, USA) and for whom the World Health
Organization (WHO) highlights the critical need for
ensuring quality of microscopy networks [11]. Early
morning sputum samples (EMS) are generally consid-
ered to yield a greater number of positive results than
spot samples, and to have higher sensitivity and specifi-
city for culture, yet the published data to support this
assumption is scarce. Factors that may influence the re-
sults of TB smear microscopy include the volume and
quality of the sputum sample collected, the time to pro-
cessing and transport conditions, and the proficiency of
the microscopist.
Routine practice in most National TB Programmes
has involved collecting three serial sputum samples,
termed a spot-morning-spot method, on the basis of a
paper by Andrews et al. published in 1959 [12], involv-
ing a spot sample collected at the first clinic visit, an
EMS brought by the patient to their second visit, and a
third spot sample collected at this visit. Later, in 2007,
the WHO changed their advice to ‘spot-morning’ on
the basis that 95–98% of positive cultures were de-
tected using the first two smears. Either practice com-
mits the patient to attend at least two clinic visits
before a diagnosis of TB can be made. The requirement
for patients to provide an EMS may prolong the diag-
nostic pathway and risks losing patients to follow up. In
2011, WHO advice was revised with a recommendation
of a two ‘spot-spot’ strategy collected on the same day;
in their guidance document, they quote a 2.8% reduc-
tion (95% CI –5.2% to 0.3%) in sensitivity using spot
samples [13]. This advice has yet to be implemented
widely and only applies to specific settings, emphasizing a
responsibility to assure the external quality assurance
scheme. Patients providing spot-spot samples rather than
awaiting EMS were shown to be less likely to be lost in
the diagnostic pathway (2% vs. 5.8%), suggesting a trade-
off needs to be made between maximising sensitivity and
keeping people in the diagnostic pathway.
In addition to their diagnostic value, qualitative and
quantitative results of sputum smears and cultures are
often used as a biomarker of treatment response in the
clinic and in clinical trials assessing new anti-tuberculous
drugs. Yet, to date, there are no published studies on the
effect of using EMS or spot samples for these purposes.
Furthermore, current evidence tends to predate the intro-
duction of fully automated liquid culture systems that are
being rolled out globally.
Herein, we aim to compare the value of EMS and spot
sputum samples and hypothesize that early morning and
spot sputum are clinically equivalent in terms of positive
yield, their sensitivity for culture in solid and liquid
media, and measures of mycobacterial load in a large,
well-characterised group of patients being treated for TB
as part of the REMoxTB study.
Methods
We undertook an analysis of all sputum sample results
from patients enrolled in the REMoxTB study (Clinical-
trials.gov NCT00864383), which has been described
previously [14, 15]. Patients were screened for recruit-
ment if at least one sputum sample was positive for
acid-fast bacilli using local laboratory procedures. As
part of the screening and enrolment procedures, pa-
tients provided two additional pre-treatment samples –
usually one spot sample at the screening visit and one
early morning sample at the second clinic attendance
prior to starting treatment. While on treatment, pa-
tients provided one sputum sample, either EMS or spot,
at each study visit. After treatment, patients attended
the clinic every 3 months for 1 year after completion
and were asked to provide one EMS on the morning of
their clinic visit with a spot sample collected during
their clinic visit. Only paired EMS and spot samples
with results in both were analysed.
Patients testing HIV positive during screening were
excluded if they were already on anti-retroviral therapy
and/or had a CD4 count of less than 250 cells/μL. We
excluded data from those patients who did not enrol in
the trial.
Microbiology
The EMS was defined as the first sputum produced by
the patient at home on the first urge to cough after wak-
ing. If more than 1 h was to elapse prior to attendance
at the study clinic, patients were advised to refrigerate
the sample or store it in a cool dark place.
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For spot samples, study staff coached patients unable to
spontaneously expectorate quality samples to take several
deep breaths, hold their breath for a moment, and repeat
this several times until coughing was induced. They would
then cough deeply and vigorously whilst breathing out.
Some patients were not able to provide requested sputum
samples at every visit. Samples were maintained at 2–8 °C
until processing.
Laboratory staff were aware that patients were enrolled
in the REMoxTB study but were blind to the treatment
allocation and clinical condition of the patient or were
only provided minimal data such as that available on a
microbiology request form. Laboratory staff requested
repeat spot samples if the sample provided, either EMS
or spot, was considered of insufficient volume (<2 mL)
or of poor quality (e.g. salivary sample); the repeat sam-
ple was included as a spot sample for the purposes of
these analyses.
Sputum type was recorded in the source documents
and the case report form. EMS and spot samples were
processed together in batches, as described in the
laboratory manual [16]. Briefly, sputum specimens were
liquefied with N-acetyl-cysteine and sodium citrate, and
decontaminated with sodium hydroxide. The decontami-
nated sample was used to make a smear and inoculate
both a solid Lowenstein–Jensen (LJ) slope and a
Mycobacteria Growth Indicator Tube (MGIT) containing
liquid media (Bactec 960, Becton Dickinson, USA). Smears
were stained using a standard Ziehl–Neelsen (ZN) staining
procedure and graded (negative, 1+, 2+, 3+, or 4+) as per
American Thoracic Society guidelines [9]. LJ slopes were
observed weekly; the week of growth up to week 8 was
recorded as a measure of mycobacterial quantification. For
liquid culture, the MGIT time-to-positivity (TTP) up to
42 days was recorded. ZN staining was used to confirm
the presence or absence of acid-fast bacilli in cultures
in solid and/or liquid media showing growth. Contam-
ination was excluded by the absence of growth on
blood agar plates. Samples flagging positive in the
MGIT that were ZN-negative with no contamination
on blood agar were considered false positives. At least
one pre- or early treatment culture was confirmed as
Mycobacterium tuberculosis complex by use of Accuprobe
(Gen-Probe, USA).
Statistical analysis
Results on paired EMS and spot samples collected at a
single visit were analysed according to stage of treat-
ment, namely samples collected prior to commencing
treatment (pre-treatment) and samples collected at
trimonthly visits in the 12 months after completion of
study drug (post-treatment). Positive yield in smear and
liquid and solid culture, and the sensitivity and specifi-
city of smear for culture, were calculated for EMS and
spot samples. Sensitivity and specificity were also calcu-
lated for the maximum positive yield of available results,
where a positive culture in either or both media was
considered positive.
The statistical significance of differences in distributions
of smear and smear grading, and culture results, was de-
termined using the Stuart–Maxwell test of marginal
homogeneity and χ2 test. Agreement between results on
EMS and spot samples is described for both binary posi-
tive/negative results, and for all results including contami-
nated and false positive (liquid culture) results. Time to
detect a positive culture was used as an inverse measure
of mycobacterial burden. Time to detection (TTD) in cul-
ture on LJ (LJ TTD) and in MGIT (MGIT TTP) in days
were recorded; a TTD of 9 weeks, i.e. 63 days, and a TTP
of 43 days was used for negative cultures on LJ and MGIT,
respectively. Differences between EMS and spot samples
were compared using Wilcoxon signed-rank test for
paired samples. Odds ratios were calculated to determine
the association between quantitative measures of myco-
bacterial burden in EMS and spot sputum samples (smear
grading, TTD of positive cultures) and unfavourable out-
come of TB treatment defined as the combined failure of
bacteriological cure and relapse within 1 year of comple-
tion of therapy as defined by culture using solid media. As
TTD of a positive culture is positively skewed, these values
were logarithmically transformed for logistic regression
analyses.
Kaplan–Meier plots of time to first positive culture after
the completion of 6 months of the study drug were gener-
ated and EMS and spot sample results compared using a
hazard ratio and the Mantel–Cox log-rank test.
An extract of the prospectively collected REMoxTB data-
base was collated for the purposes of this study after com-
pletion of the study [15], and analysed using GraphPad
PRISM and Stata 14.
Results
A total of 1115 pre-treatment and 2995 post-treatment
paired spot and EMS samples from 1931 enrolled patients
were available for analysis (Fig. 1). Patients were enrolled
between 2008 and 2012 from local clinics in South Africa
(47%), East Africa (21%), India (20%), Asia (11%) and 1%
North America. Males comprised 70% of the population.
The median age was 31 years (IQR 24–41). HIV co-
infection was detected in 139 (7%) patients; median CD4
cell count was 399 cells/μL (IQR 318–535). A table of full
baseline characteristics for the REMoxTB study patient
population is available elsewhere [13].
Smear results
Pre-treatment
Prior to treatment, spot samples were smear positive
more often than EMS (98.4% vs. 97.0%, P = 0.02) as
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shown in Table 1. Agreement between spot and EMS
samples for binary positive/negative results was 95.5%.
Somewhat paradoxically, of 1064 positive smears with a
smear grading available, 149 (14.0%) had a higher smear
grading on the spot sample than the EMS, compared to
409 (38.4%) that had a higher smear grading on EMS
compared to spot samples (P < 0.001).
Post-treatment
Spot and EMS samples had comparable proportions of
smear positive rates post-treatment (3.9% vs. 4.2%, P =
0.15; Table 1). For the binary positive or negative smear
result post-treatment, spot and EMS sample results
agreed in 98.7% of cases. Of 103 paired positive post-
treatment smears, 8 (7.8%) had a higher smear grading
on spot samples compared to 24 (23.3%), which had
higher smear grading on EMS (P = 0.002).
Culture results
Pre-treatment
Comparing 1115 paired spot-EMS pre-treatment sam-
ples, spot samples were positive more often than EMS in
LJ culture (86.5% vs. 82.2%, P = 0.006; Table 1). In MGIT
culture, both spot and EMS samples had similar positive
yields (95.0% and 93.4%, P = 0.18). Agreement between
spot and EMS samples for any culture result (positive,
negative, contaminated (including MGIT false positive))
occurred in 77.8% and 90.3% of cases for LJ and MGIT,
respectively. Ignoring contaminated and MGIT false
positive results, agreement was of 91.5% and 97.9% for
binary positive or negative results for LJ and MGIT, re-
spectively. Agreement between spot and EMS samples
for the maximum positive yield of culture results, where
either positive in MGIT or LJ was considered positive,
was 97.0%. Where paired spot and EMS samples were
both culture positive (n = 896), spot samples had longer
times to detect a positive MGIT culture than EMS sam-
ples by 1 day (median 5.5 vs. 4.5 days, P < 0.001), and
while the median LJ TTD was 14 days for both spot and
EMS samples, the significant P value provides evidence
for a similar difference (P = 0.01, Fig. 2).
Post-treatment
Post-treatment, spot and EMS samples had comparable
positive yields of culture positives in MGIT (7.7% vs. 7.6,
P = 0.85) and LJ (4.5% and 5%, respectively, P = 0.22).
Agreement between spot and EMS samples was 96.4%
and 93.7% for binary positive or negative results for LJ
and MGIT, respectively. For any culture result, including
contaminated and MGIT false-positive results, agree-
ment was 79.3% and 75.4% for LJ and MGIT,
respectively. Agreement between spot and EMS sam-
ples for the maximum positive yield of culture re-
sults, where either positive in MGIT or LJ was
considered positive, was 91.0%. Where paired spot
and EMS samples were both culture positive (n = 118),
there was no evidence of a difference in TTP in MGIT, al-
though the observed TTP in MGIT of spot samples was
slightly greater (8.23 vs. 7.5 days, P = 0.23; Fig. 2). There
were 73 paired spot and EMS sample LJ culture positives,
also with no difference in TTD (both 21 days, P = 0.72;
Fig. 2).
Contamination rates
Pre-treatment, LJ culture contamination was lower in
spot samples than EMS (8.4% vs. 10.9%, P = 0.006).
There was no difference in the combined MGIT contam-
ination and false positive rate for spot and EMS samples
Fig. 1 Flow chart of samples included in the EMS and spot study
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(3.8% vs. 5.5%, respectively, P = 0.18). Fewer contaminated
spot samples were positive on EMS than were contami-
nated EMS samples positive on the corresponding spot
sample on LJ culture (5.5% vs. 8.2%, P = 0.006), but
there was no significant difference for MGIT (3.0% vs.
4.4%, P = 0.18).
Post-treatment, the combined MGIT culture contamin-
ation and false positive rate was lower in spot samples com-
pared to EMS (14.1% vs. 16.5%, P = 0.01) but there was no
difference for LJ culture (14.0% and 14.7%, P = 0.11). Of the
contaminated samples on LJ, similar numbers were positive
in spot and EMS samples (0.4% and 0.3%), as were contam-
inated samples in MGIT (1.2% vs. 1.5%).
Predicting outcomes
Of the entire 1931 patients enrolled in the REMoxTB
study, unfavourable outcomes were documented in 226
patients (12%) [14]. There was evidence that increasing
pre-treatment smear grading predicted an unfavourable
outcome in the per protocol population for both spot
samples and EMS (non-parametric test for trend; P =
0.002 and P = 0.008, respectively; Table 2). The increased
odds of an unfavourable outcome corresponding to an
increasing smear grading for both spot samples and
EMS remained significant even when controlling for
treatment allocation. However, there was no significant
difference in post-treatment-paired spot-EMS smear re-
sults and grading, MGIT results and TTP, and LJ results
and TTD at any visit both in patients with a favourable
and unfavourable outcome (Fig. 3).
Using TTP in pre-treatment samples (an inverse meas-
ure of bacterial burden) to predict an unfavourable out-
come appeared to be significant for spot MGIT samples
(P = 0.05) but not EMS (P = 0.07) (Table 2). The result for
MGIT samples was no longer significant when treatment
allocation was included in the model. TTD of a positive
culture on LJ media pre-treatment was not predictive of
unfavourable outcome for either EMS or spot samples
(OR 0.61, P = 0.26 and OR 0.73, P = 0.51, respectively;
Table 2).
In those patients with an unfavourable outcome, post-
treatment positives were not identified sooner on spot or
EMS samples in smear (HR 1.09, P = 0.59), MGIT (HR
1.14, P = 0.35) or LJ (HR 0.99, P = 0.99) (Fig. 4). Compar-
ing paired spot-EMS sputum post-treatment in those with
an unfavourable outcome, there was no significant differ-
ence in either MGIT TTP or LJ TTD at any patient visit
(Fig. 3).
Discussion
Diagnostic samples collected prior to treatment comprise
the greatest proportion of those processed globally for TB
and have been the focus of most research in efforts to
improve early case detection using smear microscopy. In
our study, pre-treatment spot samples had a higher yield
Table 2 Odds ratios of paired EMS and spot sputum smear grading and culture time-to-detection for predicting an unfavourable
outcome (logistic regression)
Baseline predictor variable EMS Spot
OR 95% CI P value OR 95% P value
Baseline smear grading* ZN Neg 0.63 0.18–2.11 0.45 – – –
ZN 1+ 0.50 0.17–1.42 0.19 0.22 0.08–0.63 0.004
ZN 2+ 0.38 0.17–0.87 0.02 0.82 0.48–1.39 0.46
ZN 3+ 0.56 0.33–0.95 0.03 0.68 0.43–1.07 0.09
ZN 4+ Reference Reference
Log10 LJ TTD 0.61 0.26–1.45 0.26 0.73 0.29–1.87 0.51
Log10 MGIT TTP 0.38 0.13–1.10 0.07 0.29 0.08–0.99 0.05
*Unfavourable outcome is associated with increasing ZN smear for both EMS (P = 0.008) and spot (P = 0.002), non-parametric test for trend
CI confidence interval, EMS early morning sputum sample, LJ Lowenstein–Jensen, MGIT mycobacteria growth indicator tube, OR odds ratio, TTD time-to-detection,
TTP time-to-positivity, ZN Ziehl–Neelsen
Fig. 2 Time to detect positive MGIT and LJ cultures in paired EMS
and spot sputum samples collected pre- and post-treatment. Only
paired samples where both yielded positive cultures (time to posi-
tive culture < 43 days, MGIT and < 63 days, LJ) were included in this
analysis. Label in figure shows median and P value from Wilcoxon
signed rank test
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of smear positives, 98.4% versus 97.0%, and greater sensitiv-
ity for culture in either solid or liquid media compared to
EMS, thus supporting spot samples over EMS for the pur-
pose of TB diagnosis. EMS collection adds cost and com-
plexity to patients and health services and may contribute
to the considerable drop-out of patients in the diagnostic
pathway [7–10]. This strategy may compromise individual
patients and risks increased TB transmission in the com-
munity, with no useful benefit in terms of case detection.
The time to detect a positive culture in MGIT is in-
versely correlated with bacterial load [17, 18] and this
measure has been used to monitor treatment response
and to guide treatment decisions [19, 20]. In pre-
treatment samples in our study, we found EMS had faster
times to detection in MGIT by approximately 1 day prior
to treatment, perhaps owing to pre-culturing in the sam-
ple container prior to submission in the clinic as com-
pared to spot samples [17, 21, 22]. Such a small difference
is unlikely to be clinically significant. However, this differ-
ence may impact the results of molecular identification
methods that are used to confirm both the presence of M.
tuberculosis complex and genotypic resistance patterns, as
these have an operational limit for detection and interpret-
ation. As Xpert MTB/RIF (Cepheid, Sunnyvale, CA, USA)
logrank p=0.58
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Murphy et al. BMC Medicine  (2017) 15:192 Page 7 of 10
is increasingly being considered as a predictor of treat-
ment outcome, and for diagnostic use in resource-lim-
ited settings, this difference may indeed prove important
[23, 24].
We are not able to address the value of EMS com-
pared to spot samples to identify a positive TB culture in
smear-negative patients as smear positivity was an inclu-
sion criterion. The importance of this difference, if any,
is limited to those programmatic settings where cultures
are used, as opposed to the majority, which rely on
smears. Several studies in different settings have shown
a higher yield for EMS over spot samples [25, 26]. In
contrast, a sub-analysis of a large multicentre study of
spot-spot-EMS versus spot-EMS-spot samples processed
in solid media (either LJ medium or Ogawa medium) in
more than 6000 patients found that spot-spot sample
collection alone was not inferior to spot-spot-EMS and
indeed resulted in higher numbers of patients actually
providing the requested samples [6]. A separate study
comparing spot-spot-EMS compared to making two
smears from a single sample found them to have com-
parable sensitivity and specificity for culture-positive TB
[27]. Importantly, in both of these studies, and in ours
where required, patients were coached on how to pro-
vide a quality sputum sample, an intervention which has
already proven efficient in improving sputum quality
provided by women and is likely to be achievable in
programmatic settings [28]. A systematic review and
meta-analysis of front-loaded or same-day microscopy
compared to standard smear microscopy schedules
showed same-day samples to have comparable accuracy
for culture-positive TB [29]. These studies are likely to
have been influential in the WHO policy statement sup-
porting spot-spot collections [13], and are consistent with
our results. WHO guidance supports the use of direct
smears in contrast to the decontaminated samples used in
our study; however, this is unlikely to have a significant
impact given their review of studies and a systematic re-
view of bleach processing failed to demonstrate superior-
ity over direct smears [30, 31].
In our post-treatment samples spot and EMS also had
comparable yields of positive smears and cultures on
both LJ and MGIT media. Thus, the possibility that
EMS identify patients relapsing post-treatment faster
than spot samples is not supported by the data in our
study. For patients being followed up for relapse in a
programmatic setting, these data suggest that a spot
sample taken at the clinic visit suffices, with no benefit
in awaiting EMS for isolating M. tuberculosis.
In terms of predicting outcomes in our study, we iden-
tified a trend towards worse outcomes in patients with
higher mycobacterial burden on smear microscopy and
in MGIT culture, but this finding in MGIT was not sig-
nificant when adjusted for treatment allocation. There
was no association with time to detect a positive LJ
culture for either EMS or spot samples.
Microbiological culture data are routinely lost through
culture contamination and MGIT false positives. Clearly,
there is a balance to be struck between TB isolation and
culture contamination; stringent efforts to avoid con-
tamination may reduce the sensitivity of sputum culture
by any method. In our study, contamination rates were
controlled at between 3% and 8%. Little is known of the
reasons for MGIT false positives and thus practical ad-
vice to reduce these is unavailable. In our study, spot
samples tended to have lower contamination in both
MGIT and LJ and lower MGIT false positive rates than
EMS both pre- and post-treatment. Our results agree
with a study in Ugandan adolescents that found more
contamination in EMS [26]. However, they identified
non-tuberculous mycobacterial contamination to be an
issue, whereas in our study this was mainly with organ-
isms identified on blood agar. Other reported work in
this area tends not to be stratified by spot samples or
EMS, and specific studies of spot samples and EMS
generally remove contaminated samples from their ana-
lyses. Hence, contamination differences between spot
samples and EMS may have been previously overlooked.
Conclusions
In this study of patients with smear-positive TB, spot sam-
ples were found to be at least as good as EMS for identify-
ing M. tuberculosis prior to and during TB treatment and
do not support the superiority of EMS over spot samples
in a clinical trial setting. This study provides further sup-
port for the same-day, two-sample spot-spot diagnostic
process recently endorsed by the WHO for programmatic
settings. A strategy of no longer requiring EMS collections
could have an important impact on global health and may
avoid potentially catastrophic costs for individual patients
and their families when being assessed for TB.
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